Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 13/20 | 0.84 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16912970 | 1.00 | ENPP2 (0.84) | ENPP2KDM2BS1PR5KDM4ES1PR1 | |
| SCHEMBL16912972 | 0.92 | ENPP2 (0.71) | ENPP2KDM2BKDM4ES1PR1 | |
| SCHEMBL15564682 | 0.92 | ENPP2 (0.71) | ENPP2KDM2BKDM4ES1PR1 | |
| SCHEMBL16912981 | 0.91 | ENPP2 (0.71) | ENPP2KDM2B | |
| SCHEMBL15565122 | 0.91 | ENPP2 (1.00) | ENPP2KDM2BS1PR5S1PR1 | |
| SCHEMBL15564762 | 0.91 | ENPP2 (0.71) | ENPP2KDM2B | |
| SCHEMBL15565120 | 0.91 | ENPP2 (1.00) | ENPP2KDM2BS1PR5S1PR1 | |
| SCHEMBL15565605 | 0.90 | ENPP2 (0.68) | ENPP2KDM2BKDM4E | |
| SCHEMBL16912971 | 0.90 | ENPP2 (0.68) | ENPP2KDM2BKDM4E | |
| SCHEMBL20953353 | 0.89 | ENPP2 (0.75) | ENPP2S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273234-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273234-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2879674-B1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA INC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2879674-B1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA INC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20150203493-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150203493-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150203493-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2015-07-23 | — | — | US | disclosed |
| EP-2879674-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2015-06-10 | — | — | EP | disclosed |
| WO-2014025708-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273234-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | ENPP2, S1PR1, S1PR2 | ENPP2 1/4885KDM2B 3204/4885S1PR5 4/4885 |
| US-20150203493-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | ENPP2 1/4885KDM2B 3204/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.